Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 5/20 | 0.46 |
| ▸ | CTSK | P43235 | 4/20 | 0.46 |
| ▸ | CTSD | P07339 | 5/20 | 0.41 |
| ▸ | CTSV | O60911 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6927425 | 0.90 | CTSL (0.55) | CTSLCTSBCTSSCNR2CTSK | |
| SCHEMBL7464820 | 0.90 | CTSL (0.47) | CTSLCTSBCTSSSCN9APSMB5 | |
| SCHEMBL7464557 | 0.89 | GRN (0.52) | CTSLCTSBCTSSSCN9APSMB5 | |
| SCHEMBL7467469 | 0.89 | CTSL (0.47) | CTSLCTSBCTSSSCN9ACNR2 | |
| SCHEMBL6927525 | 0.88 | CTSL (0.49) | CTSLCTSBCTSSCNR2CTSK | |
| SCHEMBL6927143 | 0.88 | CTSL (0.43) | CTSLCTSBCTSSSCN9APSMB5 | |
| SCHEMBL7467318 | 0.88 | CTSL (0.53) | CTSLCTSBCTSSSCN9ACNR2 | |
| SCHEMBL7609373 | 0.88 | HSPA5 (0.49) | CTSLCTSBCTSSCNR2CTSK | |
| SCHEMBL7462272 | 0.88 | CTSL (0.50) | CTSLCTSBCTSSSCN9ACNR2 | |
| SCHEMBL7462346 | 0.88 | CTSK (0.47) | CTSLCTSBCTSSSCN9ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0983228-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-08-07 | — | — | EP | claimed |
| US-20020065230-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-05-30 | — | — | US | claimed |
| EP-0983228-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-03-08 | — | — | EP | claimed |
| WO-1998050342-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
| EP-0983228-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-08-07 | — | — | EP | disclosed |
| US-20020065230-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-05-30 | — | — | US | disclosed |
| EP-0983228-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998050342-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065230-A1 | Protease inhibitors | PRSS1, DNPEP, CTSZ | CTSL 4/4885CTSB 13/4885CTSS 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.